EcoDrugPlus

Cytochrome P450, Family 19, Subfamily A, Polypeptide 1a

Ensembl ID : ENSOSIG00000022494
Gene Symbol: CYP19A1A
1 Cross references
249 Possible Orthologues:

Cytochrome P450, Family 26, Subfamily A, Polypeptide 1

Ensembl ID : ENSOSIG00000023439
Gene Symbol: CYP26A1
1 Cross references
194 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSOSIG00000008690
Gene Symbol: CYP3A65
1 Cross references
541 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1b

Ensembl ID : ENSOSIG00000008210
Gene Symbol: DGAT1B
1 Cross references
190 Possible Orthologues:

Dihydroorotate Dehydrogenase

Ensembl ID : ENSOSIG00000009691
Gene Symbol: DHODH
1 Cross references
172 Possible Orthologues:

Dihydropyrimidine Dehydrogenase B

Ensembl ID : ENSOSIG00000017085
Gene Symbol: DPYDB
1 Cross references
211 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSOSIG00000018474
Gene Symbol: DDR2
1 Cross references
204 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSOSIG00000007607
Gene Symbol: DDR2
1 Cross references
190 Possible Orthologues:

Dopamine Receptor D1

Ensembl ID : ENSOSIG00000021374
Gene Symbol: DRD1
1 Cross references
188 Possible Orthologues:

Dopamine Receptor D1b

Ensembl ID : ENSOSIG00000006190
Gene Symbol: DRD1B
1 Cross references
198 Possible Orthologues:

Dopamine Receptor D2a

Ensembl ID : ENSOSIG00000018478
Gene Symbol: DRD2A
1 Cross references
208 Possible Orthologues:

Dopamine Receptor D3

Ensembl ID : ENSOSIG00000016587
Gene Symbol: DRD3
1 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).